Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
XCUR
XCUR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
XCUR News
Exicure Partners with Adbiotech for Burixafor Development
Apr 23 2026
NASDAQ.COM
Exicure Partners with Adbiotech for Burixafor Development
Apr 23 2026
Newsfilter
Exicure Partners with Adbiotech for Combination Therapy Development
Apr 23 2026
Yahoo Finance
EXICURE AND ADBIOTECH ENTER CO-DEVELOPMENT PARTNERSHIP FOR BURIXAFOR (GPC-100)
Apr 22 2026
moomoo
Exicure Reports Liquidity Crisis with FY GAAP EPS of -$0.79
Mar 26 2026
seekingalpha
Exicure (XCUR) to Present 89.7% Success Rate Data at ASTCT Meeting
Jan 21 2026
Newsfilter
Exicure Stock Rises 41% Following Positive Phase 2 Results for Multiple Myeloma Treatment
Dec 09 2025
NASDAQ.COM
Crude Oil Falls 1%; AutoZone Stock Declines Following Q1 Earnings Report
Dec 09 2025
Benzinga
Exicure Soars Following Promising Cell-Enhancing Outcomes in Blood Cancer Study
Dec 09 2025
Benzinga
Dow Rises More Than 100 Points as Campbell's Reports Positive Earnings
Dec 09 2025
Benzinga
Mama's Creations Stock Rises Over 13%; Check Out 20 Stocks Making Moves in Premarket Trading
Dec 09 2025
Benzinga
Exicure Rises Following Burixafor Trial Results in Multiple Myeloma
Dec 09 2025
NASDAQ.COM
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Dec 09 2025
NASDAQ.COM
Exicure Reports 90% Success in Phase 2 Trial for Burixafor in Hematologic Diseases
Dec 08 2025
Globenewswire
Exicure Reports 90% Success in Phase 2 Trial of Burixafor for Multiple Myeloma
Dec 08 2025
Newsfilter
Exicure, Inc. Reports Q3 Loss of $2.44 Million
Nov 08 2025
NASDAQ.COM
Show More News
